On the other hand, LNCaP prostate cancer cells that are inherited with both nuclear AR and ZIP-9, respond to testosterone by initiating metastatic migratory mechanism [66], and therefore testosterone lowering treatment in transgender women may be favorable in controlling metastasis if the cancer cells carry nuclear AR and ZIP-9. Here, SLC39A9 is linked to prostate cancer.